Cullinan Therapeutics Stock (NASDAQ:CGEM)

Forecast Ownership Financials Chart

Previous Close

$8.06

52W Range

$5.68 - $17.50

50D Avg

$7.06

200D Avg

$8.11

Market Cap

$501.54M

Avg Vol (3M)

$837.27K

Beta

-0.12

Div Yield

-

CGEM Company Profile

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Industry

Medical - Pharmaceuticals

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

111

IPO Date

Jan 08, 2021

Website

CGEM Performance

CGEM Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	$18.94M
Operating Income	$-191.09M	$144.65M	$-67.95M
Net Income	$-153.16M	$111.21M	$-65.04M
EBITDA	$-190.34M	$151.41M	$-67.90M
Basic EPS	$-3.69	$2.46	$-1.47
Diluted EPS	$-3.69	$2.38	$-1.47

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
SY	So-Young International Inc.
CYH	Community Health Systems, Inc.
CBLL	CeriBell, Inc.
FDMT	4D Molecular Therapeutics, Inc.
MBX	MBX Biosciences, Inc. Common Stock
PACB	Pacific Biosciences of California, Inc.
ADCT	ADC Therapeutics S.A.
SLDB	Solid Biosciences Inc.
RCKT	Rocket Pharmaceuticals, Inc.
VREX	Varex Imaging Corporation